162 related articles for article (PubMed ID: 30649440)
1. Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Gray V; Briggs S; Palles C; Jaeger E; Iveson T; Kerr R; Saunders MP; Paul J; Harkin A; McQueen J; Summers MG; Johnstone E; Wang H; Gatcombe L; Maughan TS; Kaplan R; Escott-Price V; Al-Tassan NA; Meyer BF; Wakil SM; Houlston RS; Cheadle JP; Tomlinson I; Church DN
J Natl Cancer Inst; 2019 Aug; 111(8):828-836. PubMed ID: 30649440
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
Summers MG; Maughan TS; Kaplan R; Law PJ; Houlston RS; Escott-Price V; Cheadle JP
Eur J Cancer; 2020 Jan; 124():56-63. PubMed ID: 31734605
[TBL] [Abstract][Full Text] [Related]
3. Association of Genetic Polymorphisms in
Posadas-Mondragón A; Aguilar-Faisal JL; Zuñiga G; Magaña JJ; Santiago-Cruz JA; Guillén-Salomón E; Alcántara-Farfán V; Arellano-Flores ML; Salas-Benito JS; Neri-Bazán RM; Luna-Rojas L; Avila-Trejo AM; Chávez-Negrete A
Viruses; 2020 Oct; 12(11):. PubMed ID: 33138336
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse.
Chen DN; Song CG; Yu KD; Jiang YZ; Ye FG; Shao ZM
PLoS One; 2015; 10(7):e0133184. PubMed ID: 26226228
[TBL] [Abstract][Full Text] [Related]
6. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Wood G; Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
Anticancer Drugs; 2017 Jun; 28(5):546-550. PubMed ID: 28252533
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.
Ostojic N; Radevic T; Kandolf Sekulovic L; Djordjevic B; Jaukovic L; Stepic N; Supic G
Melanoma Res; 2022 Oct; 32(5):309-317. PubMed ID: 35855659
[TBL] [Abstract][Full Text] [Related]
8. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Saunders MP; Iype R; Kelly C; Crosby J; Kerr R; Harkin A; Allan K; McQueen J; Pearson SR; Cassidy J; Medley LC; Raouf S; Harrison M; Brewster A; Rees C; Ellis R; Thomas AL; Churn M; Iveson T; Maka N
Clin Colorectal Cancer; 2023 Jun; 22(2):231-237. PubMed ID: 36967267
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
10. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr D; Gray V; West H; Houlston RS; Escott-Price V; Cheadle JP
Int J Cancer; 2021 Nov; 149(9):1713-1722. PubMed ID: 34270794
[TBL] [Abstract][Full Text] [Related]
12. MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
Negandhi AA; Hyde A; Dicks E; Pollett W; Younghusband BH; Parfrey P; Green RC; Savas S
PLoS One; 2013; 8(4):e61469. PubMed ID: 23626689
[TBL] [Abstract][Full Text] [Related]
13. TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer.
Proença MA; de Oliveira JG; Cadamuro AC; Succi M; Netinho JG; Goloni-Bertolo EM; Pavarino ÉC; Silva AE
World J Gastroenterol; 2015 Jul; 21(25):7730-41. PubMed ID: 26167073
[TBL] [Abstract][Full Text] [Related]
14. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
[TBL] [Abstract][Full Text] [Related]
15. Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.
Park HA; Seibold P; Edelmann D; Benner A; Canzian F; Alwers E; Jansen L; Schneider M; Hoffmeister M; Brenner H; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):352-361. PubMed ID: 34862210
[TBL] [Abstract][Full Text] [Related]
16. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
18. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
19. TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection.
Sghaier I; Zidi S; Mouelhi L; Ghazoueni E; Brochot E; Almawi WY; Loueslati BY
Br J Biomed Sci; 2019 Jan; 76(1):35-41. PubMed ID: 30421643
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis.
Slattery ML; Herrick JS; Bondurant KL; Wolff RK
Int J Cancer; 2012 Jun; 130(12):2974-80. PubMed ID: 21792899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
